Home > Bladder Cancer

Bladder Cancer

Bladder cancer is a malignant tumor originating from the urothelium in the bladder tissue caused by the uncontrolled abnormal proliferation of bladder lining cells. It is one of the most common malignant tumors of the urinary system, ranked 7th among male malignant tumors, and is also a common malignant tumor among females¹.

Based on whether the tumor invades the bladder muscle, bladder cancer can be divided into non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC).

1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87.

Unmet Clinical Needs

For NMIBC patients – no oral medication, painful intravesical administration, severe adverse reactions.

Limitations of Traditional Surgical Treatment

TURBT: Patients have a high recurrence rate after TURBT, at about 60% within five years. Some will progress to MIBC.
Postoperative adjuvant intravesical therapy, including intravesical chemotherapy or Bacille Calmette-Guerin (BCG):

When intravesical instillation therapies fail, currently there is no good second-line treatment option. A treatment with new mechanism is urgently needed, to prevent or delay radical bladder cystectomy.
Bladder intravesical therapies result in poor tolerance. Intravesical chemotherapy or BCG causes high rate of adverse reactions, such as urethral irritation, hematuria, pain that some patients cannot tolerate.
Intravesical therapies are invasive procedures, with long dosing cycles and poor patient compliance. Patients urgently need a new treatment with significant efficacy, good safety and convenient administration.

Asieris Solution

Centered around APL-1202 (Vesique^®), create an integrated diagnosis-treatment solution for treating bladder cancer.

APL-1202 (Vesique^®)

APL-1202 is the world’s first oral targeted NMIBC therapy that has entered the pivotal phase II clinical trial. It is expected to become the first second-line treatment option for intermediate- and high-risk chemotherapy-relapsed NMIBC patients.

APL-1202 is safe and effective for high-risk NMIBC relapsed by chemotherapy infusion

Phase II clinical trial results show that APL-1202 is significantly more effective than the current chemotherapy infusion with good safety.

The convenient oral administration also frees patients from the pain of intravesical infusion.

APL-1706 (Hexvix^®)

APL-1706 is the only approved diagnostic imaging agent to support detection or surgery of patients with bladder cancer. In combination with Blue Light Cystoscopy, it can effectively improve the detection rate of non-muscle invasive bladder cancer (NMIBC), especially carcinoma in situ, enable better TURBT procedures and reduce recurrences.

The only approved diagnostic imaging agent to support detection or surgery of patients with bladder cancer.
Approved and launched on market in over 30 countries.
Listed in the NMIBC guidelines as a first-line treatment in both US and Europe.

Complete integrated diagnosis-treatment solution

Introducing APLD-2101 from Uroviu, a single-use endoscopy product for diagnosing bladder diseases.

Provide full-range solutions for doctors and patients by integrating innovative products, covering bladder cancer diagnosis, treatment, and patient surveillance.

High Market Demand

Large base of bladder cancer patients with high recurrence rate and long survival time.

New Bladder Cancer Patients Worldwide (x1,000)

New Bladder Cancer Patients in China (x1,000)

NMIBC

Accounts for 75% of bladder cancer patients.

High recurrence rate after surgery, at about 60% within five years.

Data source: Frost & Sullivan